Roche's Experimental Eye Drug Shows Vision Improvements in Clinical Trials
Roche announced positive one-year results from two late-stage clinical trials for its experimental eye drug vamikibart. The treatment helped patients maintain vision improvements, potentially serving as an alternative to steroid-based therapies that carry significant side effects. The findings were presented at a medical conference and highlight the potential of Roche's new therapy in treating chronic retinal diseases such as non-infectious uveitis or macular edema. If approved, vamikibart could offer patients long-term benefits with fewer risks than current treatment options.
Tickers: $RHHBY